COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Seegers, Valérie; Rousseau, Guillaume; Zhou, Ke; Blanc-Lapierre, Audrey; Bigot, Frédéric; Mahammedi, Hakim; Lambert, Aurélien; Moreau-Bachelard, Camille; Campone, Mario; Conroy, Thierry; Penault‐Llorca, Frédérique; Boisdron‐Celle, Michèle; Bellanger, Martine; Raoul, Jean‐Luc

doi:10.3390/cancers14225547

Cited by 2 publications

(3 citation statements)

References 33 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We showed that both populations (CPs and HCWs) had a similar prevalence of COVID-19 infection, noted the major diagnostic importance of anosmia and the high proportion of asymptomatic cases among CPs, and demonstrated that the seropositivity, high after the first vaccine among HCWs and low among CPs, was close to 100% after the second injection in both populations. Unfortunately, we, as others, observed some infections in vaccinated populations [12][13][14]. The aim of the present article is to describe these vaccine breakthrough infections in both cohorts.…”

Section: Introductionmentioning

confidence: 78%

See 1 more Smart Citation

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Seegers,

Rousseau,

Zhou

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; n = 935) vaccinated against COVID-19, we noticed the following: i/after vaccination, 4.4% of HCWs and 5.8% of CP were infected; ii/no characteristic was associated with post-vaccine COVID-19 infections among HCWs; iii/CP who developed infections were younger, more frequently women (NS), more frequently had gastrointestinal, gynecological, or breast cancer and a localized cancer stage; iv/CP vaccinated while receiving chemotherapy or targeted therapy had (NS) more breakthrough infections after vaccination than those vaccinated after these treatments; the opposite was noted with radiotherapy, immunotherapy, or hormonotherapy; v/most COVID-19 infections occurred either during the Alpha wave (11/41 HCW, 20/49 CP), early after the first vaccination campaign started, or during the Omicron wave (21/41 HCW, 20/49 CP), more than 3 months after the second dose; vi/risk of infection was not associated with values of antibody titers; vii/the outcome of these COVID-19 infections after vaccination was not severe in all cases. To conclude, around 5% of our CPs or HCWs developed a COVID-19 infection despite previous vaccination. The outcome of these infections was not severe.

show abstract

Section: Introductionmentioning

confidence: 78%

“…This section has been reported previously [12][13][14]. The PAPESCO-19 (Patients et Personnels de Santé des Centres de Lutte Contre le Cancer pendant l'épidémie de COVID- 19) prospective multicenter cohorts study took place in 4 French Comprehensive Cancer Centers, located in Angers, Clermont-Ferrand, Nancy, and Nantes.…”

Section: Methodsmentioning

confidence: 99%

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Seegers,

Rousseau,

Zhou

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…We used data from the PAPESCO-19 (PAtients et PErsonnels de Sante ´des Centres de Lutte Contre le Cancer pendant l'e ´pide ´mie de COVID-19), a multicenter cohort study that took place in 4 French Comprehensive Cancer Centers, located in Angers, Clermont-Ferrand, Nancy, and Nantes, as previously reported [22,23]. Participants were eligible irrespective of whether they had COVID-19 symptoms or not.…”

Section: Methodsmentioning

confidence: 99%

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

Zhou,

Robert,

Seegers

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Longer times between diagnosis and treatments of cancer patients have been estimated as effects of the COVID-19 pandemic. However, relatively few studies attempted to estimate actual delay to treatment at the patient level. Objective To assess changes in delays to first treatment and surgery among newly diagnosed patients with localized breast cancer (BC) during the COVID-19 pandemic. Methods We used data from the PAPESCO-19 multicenter cohort study, which included patients from 4 French comprehensive cancer centers. We measured the delay to first treatment as the number of days between diagnosis and the first treatment regardless of whether this was neoadjuvant chemotherapy or surgery. COVID-19 pandemic exposure was estimated with a composite index that considered both the severity of the pandemic and the level of lockdown restrictions. We ran generalized linear models with a log link function and a gamma distribution to model the association between delay and the pandemic. Results Of the 187 patients included in the analysis, the median delay to first treatment was 42 (IQR:32–54) days for patients diagnosed before and after the start of the 1st lockdown (N = 99 and 88, respectively). After adjusting for age and centers of inclusion, a higher composite pandemic index (> = 50 V.S. <50) had only a small, non-significant effect on times to treatment. Longer delays were associated with factors other than the COVID-19 pandemic. Conclusion We found evidence of no direct impact of the pandemic on the actual delay to treatment among patients with localized BC.

show abstract

COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Cited by 2 publications

References 33 publications

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

Contact Info

Product

Resources

About